Transplant immunosuppressive drugs are used by patients who have had organ transplant surgery in the past. These drugs are helpful in protecting patients against rejection of the transplanted foreign organ by their own bodies. Moreover, the rising prevalence of chronic diseases such as cardiovascular disease, diabetes, cancer, and asthma are expected to increase the demand for organ transplants, which will further boost the transplant immunosuppressive drugs market during the forecast period. Technological advancements made by biotechnology and medical device companies in novel transplant products, an increasing number of tissue banks, and rising healthcare expenditure across various countries are anticipated to drive the overall growth of the market. Based on the report published by the United Network for Organ Sharing (UNOS) on organ transplantation, it was estimated that the total number of transplants that were performed in 2018 was around 26,448. This included kidney (21,167), liver (8,250), heart (3,408), lung (2,530), kidney and pancreas (836), pancreas (192), intestine (104), heart/lung (32), and vascular allograft (11) transplant procedures.
One of the primary reasons driving the market's growth is the increased organ transplant surgeries. According to the health resources and services administration, 39,000 transplants were performed in 2020, and 106,795 men, women, and children are on the waiting list for organ transplants in the United States. Moreover, the rising incidence of vital organ failure and increasing awareness about organ procurement and transplantation are anticipated to drive the transplant immunosuppressive drug market during the forecast period. According to the data published by Transplant Australia, the Australian organ donation rate is currently 18.0 donors per million. In 2020, 463 deceased organ donors and 182 living donors gave 1,452 Australians a new chance in life. The most common transplanted organs are the kidney, liver, heart, lungs, and pancreas. Furthermore, the increasing incidence of chronic diseases is expected to increase the demand for organ transplant procedures, which will further drive the overall market growth. Advancement in tissue engineering and organ transplantation is expected to positively increase the market growth. Tissue engineering helps in replacing failed organs with the help of tailored organs. It helps in creating a functional artificially produced organ. According to the U.S. government’s organ donation and transplantation report, more than 100,000 patients are on the 2019 waiting list for organ transplantation, and the main problem that is arising is the shortage of organ donations.
The increasing demand for organ transplants has led to the entry of several new players in the transplant immunosuppressive drug market. To increase their clientele as well as increase their market share in the upcoming years, many of these market players have taken various strategic actions like partnerships and the development of novel solutions, which are expected to keep the market competitive and constantly evolving. Major market players like Astellas Pharma Inc. and Novartis Pharmaceuticals Corporation, among others, have been covered along with their relative competitive strategies. The report also mentions recent deals and investments by different market players over the last few years. The company profiles section details the business overview, financial performance (public companies) for the past few years, key products and services being offered, along with the recent deals and investments of these important players in the transplant immunosuppressive drugs market.
Market Drivers
Rising organ transplant surgeries
One of the primary reasons driving the market's growth is the increased organ transplant surgeries. According to the health resources and services administration, 39,000 transplants were performed in 2020, and 106,795 men, women, and children are on the waiting list for organ transplants in the United States. Moreover, the rising incidence of vital organ failure and increasing awareness about organ procurement and transplantation are anticipated to drive the transplant immunosuppressive drug market during the forecast period. According to the data published by Transplant Australia, the Australian organ donation rate is currently 18.0 donors per million. In 2020, 463 deceased organ donors and 182 living donors gave 1,452 Australians a new chance in life. The most common transplanted organs are the kidney, liver, heart, lungs, and pancreas. Furthermore, the increasing incidence of chronic diseases is expected to increase the demand for organ transplant procedures, which will further drive the overall market growth. Advancement in tissue engineering and organ transplantation is expected to positively increase the market growth. Tissue engineering helps in replacing failed organs with the help of tailored organs. It helps in creating a functional artificially produced organ. According to the U.S. government’s organ donation and transplantation report, more than 100,000 patients are on the 2019 waiting list for organ transplantation, and the main problem that is arising is the shortage of organ donations.
Competitive Insights
The increasing demand for organ transplants has led to the entry of several new players in the transplant immunosuppressive drug market. To increase their clientele as well as increase their market share in the upcoming years, many of these market players have taken various strategic actions like partnerships and the development of novel solutions, which are expected to keep the market competitive and constantly evolving. Major market players like Astellas Pharma Inc. and Novartis Pharmaceuticals Corporation, among others, have been covered along with their relative competitive strategies. The report also mentions recent deals and investments by different market players over the last few years. The company profiles section details the business overview, financial performance (public companies) for the past few years, key products and services being offered, along with the recent deals and investments of these important players in the transplant immunosuppressive drugs market.
Segmentation
By Type
- Induction Drugs
- Maintenance Drugs
By Application
- Tissue Transplantation
- Organ Transplantation
By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- Germany
- France
- United Kingdom
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- Israel
- Others
- Asia Pacific
- China
- Japan
- South Korea
- India
- Others
Table of Contents
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Dynamics
5. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TYPE
6. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY TYPE
7. TRANSPLANT IMMUNOSUPPRESSIVE DRUGS MARKET BY GEOGRAPHY
8. COMPETITIVE INTELLIGENCE
9. COMPANY PROFILES
Companies Mentioned
- Astellas Pharma Inc.
- Bristol-Myers Squibb Company
- Sanofi Genzyme
- Novartis Pharmaceuticals Corporation
- Mylan N.V.
- Hoffmann-La Roche Ltd.
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 102 |
Published | April 2022 |
Forecast Period | 2020 - 2027 |
Estimated Market Value ( USD | $ 8.22 billion |
Forecasted Market Value ( USD | $ 10.34 billion |
Compound Annual Growth Rate | 3.3% |
Regions Covered | Global |
No. of Companies Mentioned | 6 |